β-Catenin expression in benign and malignant pleural disorders

International Journal of Clinical and Experimental Pathology

Volumn 4, Issue 8, 2011, Pages 742-747

  Anani, Waseem ^a   Bruggeman, Richard ^b   Zander, Dani S ^b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Catenin; Mesothelial hyperplasia; Mesothelioma; Pleura; Wnt

Indexed keywords

BETA CATENIN; CTNNB1 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BIOSYNTHESIS; DIFFERENTIAL DIAGNOSIS; EPITHELIUM; HUMAN; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; METABOLISM; PATHOLOGY; PLEURA; PLEURA TUMOR; PLEURISY;

BETA CATENIN; DIAGNOSIS, DIFFERENTIAL; EPITHELIUM; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; PLEURA; PLEURAL NEOPLASMS; PLEURISY; TUMOR MARKERS, BIOLOGICAL;

EID: 84856698418     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Attanoos RL, Webb R and Gibbs AR. CD44H expression in reactive mesothelium, pleural mesothelioma and pulmonary adenocarcinoma. Histopathology 1997; 30: 260-263.
2. Attanoos RL, Griffin A and Gibbs AR. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, Pglycoprotein and Bcl-2. Histopathology 2003; 43: 231-238.
3. Cai YC, Roggli V, Mark E, Cagle PT and Fraire AE. Transforming growth factor alpha and epidermal growth factor receptor in reactive and malignant mesothelial proliferations. Arch Pathol Lab Med 2004; 128: 68-70.
4. Cakir C, Gulluoglu MG and Yilmazbayhan D. Cell proliferation rate and telomerase activity in the differential diagnosis between benign and malignant mesothelial proliferations. Pathology 2006; 38: 10-15.
5. Dejmek A, Hjerpe A. Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis. Cytopathology 2000; 11: 8-17.
6. Hasteh F, Lin GY, Weidner N and Michael CW. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions. Cancer Cytopathol 2010; 118: 90-96.
7. Hanley KZ, Facik MS, Bourne PA, Yang Q, Spaulding BO, Bonfiglio TA and Xu H. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions. Cancer 2008; 114: 49-56.
8. Ikeda K, Tate G, Suzuki T, Kitamura T and Mitsuya T. Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations. Diagn Cytopathol 2011; 39: 395-401.
9. Ikeda K, Tate G, Suzuki T, Kitamura T and Mitsuya T. IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology. Hum Pathol 2010; 41: 745-750.
10. Kato Y, Tsuta K, Seki K, Maeshima AM, Watanabe S, Suzuki K, Asamura H, Tsuchiya R and Matsuno Y. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol 2007; 20: 215-220.
11. Sato A, Torii I, Okamura Y, Yamamoto T, Nishigami T, Kataoka TR, Song M, Hasegawa S, Nakano T, Kamei T and Tsujimura T. Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium. Mod Pathol 2010; 23: 1458-1466.
12. Schonherr A, Bayer M and Bocking A. Diagnostic and prognostic value of Ki67 proliferation fraction in serous effusions. Cell Oncol 2004; 26: 57-62.
13. Shi M, Fraire AE, Chu P, Cornejo K, Woda BA, Dresser K, Rock KL and Jiang Z. Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation. Am J Surg Pathol 2011; 35: 878-882.
14. Wolanski KD, Whitaker D, Shilkin KB and Henderson DW. The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses. Cancer 1998; 82: 583-590.
15. Yuan Y, Nymoen DA, Stavnes HT, Rosnes AK, Bjorang O, Wu C, Nesland JM and Davidson B. Tenascin-X is a novel diagnostic marker of malignant mesothelioma. Am J Surg Pathol 2009; 33: 1673-1682.
16. Saad RS, Cho P, Liu YL and Silverman JF. The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study. Diagn Cytopathol 2005; 32: 156-159.
17. Morin PJ. beta-catenin signaling and cancer. Bioessays 1999; 21: 1021-1030.
18. Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev 2007; 17: 45-51.
19. Uematsu K, Kanazawa S, You L, He B, Xu Z, Li K, Peterlin BM, McCormick F and Jablons DM. Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-catenin. Cancer Res 2003; 63: 4547-4551.
20. Lee AY, Raz DJ, He B and Jablons DM. Update on the molecular biology of malignant mesothelioma. Cancer 2007; 109: 1454-1461.
21. Abutaily AS, Collins JE and Roche WR. Cadherins, catenins and APC in pleural malignant mesothelioma. J Pathol 2003; 201: 355-362.
22. Dai Y, Bedrossian CW and Michael CW. The expression pattern of beta-catenin in mesothelial proliferative lesions and its diagnostic utilities. Diagn Cytopathol 2005; 33: 320-324.
23. Ben Ze'ev A, Shtutman M and Zhurinsky J. The integration of cell adhesion with gene expression: the role of beta-catenin. Exp Cell Res 2000; 261: 75-82.
24. Andino L, Cagle PT, Murer B, Lu L, Popper HH, Galateau-Salle F, Sienko AE, Barrios R and Zander DS. Pleuropulmonary desmoid tumors: immunohistochemical comparison with solitary fibrous tumors and assessment of betacatenin and cyclin D1 expression. Arch Pathol Lab Med 2006; 130: 1503-1509.